John David Rhodes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
John David Rhodes has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Ajit Kambil
Director of Deloitte Services LP, Boston, Massachussetts, USA and globally leads Deloitte Research studies
1 shared publication- Ian Charles Hunter
Institute of Pollard, University of Leeds, Leeds, U.K.
1 shared publication Laura Eselius
Manager and leads the Life Sciences and Health Care sector of Deloitte Research, Deloitte Services LP, Boston, MAssachussetts, USA
1 shared publicationMohan Nimmagadda
Assistant Manager in Life Sciences and Health Care, Deloitte Research, Deloitte Services LP, Hyderabad, India
1 shared publicationR.T. (Terry) Hisey
US Managing Principal‐Life Sciences, Deloitte Consulting LLP, Philadelphia, Pennsylvania, USA
1 shared publication- Rhiannon Harries
University of Nottingham
1 shared publication
Latest Publications
- 1 May 2023
- Published by Duke University Press in differences
- Vol. 34 (1) , 14-19
Aestheticism
- 1 June 2022
- Published by Intellect in Journal of Italian Cinema & Media Studies
- Vol. 10 (3) , 399-406
Lands - seas - bodies: On the cinema of Gianfranco Rosi
- 1 June 2022
- Published by Intellect in Journal of Italian Cinema & Media Studies
- Vol. 10 (3) , 399-406
Lands - seas - bodies: On the cinema of Gianfranco Rosi
- 1 June 2022
- Published by Intellect in Journal of Italian Cinema & Media Studies
- Vol. 10 (3) , 421-433
Intimate disclosure: Below Sea Level and documentary humanism
Gianfranco Rosi’s mode of filmmaking apprehends the human ‘subject’ of documentary cinema in its uncertainty and unpredictability. Rosi’s cinema can be situated in the context of observational cinema, and like other filmmakers working in this vein, he focuses his camera on human subjects who we come to know across his films’ duration. In Below Sea Level (2009), Rosi focuses on the lives of people living marginal existences, on the edges of society, in a desert in southern California. These people disclose themselves (and are disclosed by Rosi’s shooting and editing) in an elliptical fashion that frustrates the desire for complete knowledge about their lives. In this method of intimate disclosure, in which there is a refusal to coax reassuring certainties from the people encountered in making this film, Rosi demonstrates the possibility of a humanist documentary cinema, insofar as ‘human’ in ‘humanist’ refers to an unpredictable becoming.
- 1 June 2022
- Published by Intellect in Journal of Italian Cinema & Media Studies
- Vol. 10 (3) , 421-433
Intimate disclosure: Below Sea Level and documentary humanism
Gianfranco Rosi’s mode of filmmaking apprehends the human ‘subject’ of documentary cinema in its uncertainty and unpredictability. Rosi’s cinema can be situated in the context of observational cinema, and like other filmmakers working in this vein, he focuses his camera on human subjects who we come to know across his films’ duration. In Below Sea Level (2009), Rosi focuses on the lives of people living marginal existences, on the edges of society, in a desert in southern California. These people disclose themselves (and are disclosed by Rosi’s shooting and editing) in an elliptical fashion that frustrates the desire for complete knowledge about their lives. In this method of intimate disclosure, in which there is a refusal to coax reassuring certainties from the people encountered in making this film, Rosi demonstrates the possibility of a humanist documentary cinema, insofar as ‘human’ in ‘humanist’ refers to an unpredictable becoming.
- 29 February 2008
- Published by Emerald Publishing in Journal of Business Strategy
- Vol. 29 (2) , 31-42
Managing pathways to convergence in the life sciences industry
Purpose: Convergence in the life sciences and health care industries – the combining of two or more of drugs, diagnostics and devices to create an improved health care product – is leading to new opportunities for business growth and product differentiation. This report aims to examine the issues around convergence, including the drivers, risks and regulatory issues.Design/methodology/approach: This report is based on industry and literature reviews and builds on research carried out by Deloitte Research on the life sciences and health care industry.Findings: The paper finds that technological advances, evolving health care needs and shifting market conditions are creating favourable conditions for convergence. Developing convergent technologies, however, has risks and uncertainties that life sciences companies need to consider along with regulatory issues. Cross‐sector partnerships are becoming more of a necessity and reality for health care firms, who have to be aware of the many operational and ownership issues involved.Practical implications: Market pressures and opportunities are motivating life sciences firms of all types and sizes to invest in convergence. Convergent technology is transforming cardiovascular care, orthopedic treatment, tissue wound management and other clinical areas by creating solutions that are less invasive, less painful, more patient‐specific, more convenient and sometimes more affordable. Consequently, players from all sectors are entering the competition for R&D assets, setting up new rivalries and alliances.Originality/value: In mapping the many factors surrounding convergence in the life sciences industry, this report enables firms to evaluate their own opportunities and priorities. It proposes a framework that companies can use to decide which pathway to convergence is best for them.
- 29 February 2008
- Published by Emerald Publishing in Journal of Business Strategy
- Vol. 29 (2) , 31-42
Managing pathways to convergence in the life sciences industry
Purpose: Convergence in the life sciences and health care industries – the combining of two or more of drugs, diagnostics and devices to create an improved health care product – is leading to new opportunities for business growth and product differentiation. This report aims to examine the issues around convergence, including the drivers, risks and regulatory issues.Design/methodology/approach: This report is based on industry and literature reviews and builds on research carried out by Deloitte Research on the life sciences and health care industry.Findings: The paper finds that technological advances, evolving health care needs and shifting market conditions are creating favourable conditions for convergence. Developing convergent technologies, however, has risks and uncertainties that life sciences companies need to consider along with regulatory issues. Cross‐sector partnerships are becoming more of a necessity and reality for health care firms, who have to be aware of the many operational and ownership issues involved.Practical implications: Market pressures and opportunities are motivating life sciences firms of all types and sizes to invest in convergence. Convergent technology is transforming cardiovascular care, orthopedic treatment, tissue wound management and other clinical areas by creating solutions that are less invasive, less painful, more patient‐specific, more convenient and sometimes more affordable. Consequently, players from all sectors are entering the competition for R&D assets, setting up new rivalries and alliances.Originality/value: In mapping the many factors surrounding convergence in the life sciences industry, this report enables firms to evaluate their own opportunities and priorities. It proposes a framework that companies can use to decide which pathway to convergence is best for them.
- 1 May 2001
- Published by Wiley in International Journal of Circuit Theory and Applications
- Vol. 29 (3) , 251-266
Synthesis of predistorted reflection-mode hybrid prototype networks with symmetrical and asymmetrical characteristics
- 1 May 2001
- Published by Wiley in International Journal of Circuit Theory and Applications
- Vol. 29 (3) , 251-266
Synthesis of predistorted reflection-mode hybrid prototype networks with symmetrical and asymmetrical characteristics